Friday, 23 October 2026European Markets

MOPOLI Stock 9.65% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with MOPOLI (MOP.BR) jumping 9.65% to €250.00 on Tuesday while BEL 20 dropped 0.24% to €3,663.60.

MOPOLI's last close was €240.00, 14.89% below its 52-week high of €282.00.

About MOPOLI

Palmboomen Cultuur Maatschappij Mopoli (Palmeraies De Mopoli) N.V. invests in tropical agro industry projects in Belgium. The company was incorporated in 1912 and is headquartered in Brussels, Belgium. Palmboomen Cultuur Maatschappij Mopoli (Palmeraies De Mopoli) N.V. is a subsidiary of Geselfina SA.

Earnings Per Share

As for profitability, MOPOLI has a trailing twelve months EPS of €5.14.

PE Ratio

MOPOLI has a trailing twelve months price to earnings ratio of 48.64. Meaning, the purchaser of the share is investing €48.64 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 0.7%.

Moving Average

MOPOLI's worth is under its 50-day moving average of €256.84 and under its 200-day moving average of €262.13.

More news about MOPOLI (MOP.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,426 source documents archived
Query this data → isubstrate.com